Skip to main content
    P

    Precigen Inc (PGEN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.30
    -0.24 (-5.29%)

    Market Cap: $1.63B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Precigen Inc (PGEN) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Precigen (PGEN) trades at 98.6x trailing earnings and 9.9x sales. Its P/S of 9.9x is below its 5-year median of 50.7x. Its forward P/E is 7.0x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 1308.6% higher over the next year.

    MultipleValue
    P/E (trailing)98.6x
    Forward P/E7.0x
    Price to sales9.9x
    Price to book18.4x
    EV/EBITDA42.2x
    PEGN/A
    FCF yield-4.8%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 52.2% below 20.7x and its P/B is 291.5% above 4.7x.

    MultipleCurrent5-year median10-year median
    P/S9.9x50.7x20.7x
    P/B18.4x4.8x4.7x
    Medians of month-end values through Oct 2026: 51 to 54 months (5-year) and 102 to 114 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 2.4x in 2017 to 347.0x in 2018.

    Year endPriceP/SP/B
    2025$4.18145.1x62.6x
    2024$1.1274.5x8.5x
    2023$1.3452.2x2.8x
    2022$1.5211.3x2.5x
    2021$3.7144.9x6.9x
    2020$10.2045.7x27.1x
    2019$5.489.8x11.9x
    2018$6.54347.0x2.4x
    2017$11.522.4x2.6x
    2016$24.3015.0x5.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About PGEN

    What is PGEN's forward P/E ratio?

    Precigen has a forward P/E ratio of 7.0x.

    What is PGEN's price to sales ratio?

    Precigen has a price to sales ratio of 9.9x.